The FDA's Drugs@FDA database lists a supplement approval dated 29 September for Avtozma (tocilizumab-anoh), a tocilizumab biosimilar from Celltrion, under BLA 761498.
The database entry does not describe what the supplement changed. Supplements can cover manufacturing, labelling, presentation or new uses, and many are administrative. Without the label change itself, no clinical conclusion should be drawn.
Tocilizumab biosimilars widen supply and may lower cost. The status of this product in India is not known from this notice, and CDSCO action has not been reported here.
- No change to prescribing follows from this notice alone; the content of the supplement is not stated.
- Check the updated label before assuming any new indication or presentation.
- Use generic names in prescribing records alongside the biosimilar brand to support traceability.
- Apply the usual tocilizumab monitoring — neutrophils, platelets, liver enzymes and lipids — whichever product is used.
Why it matters
Biosimilar activity signals growing supply of IL-6 blockade, which matters for access and cost.
Don't overread it
A licence supplement is not a new indication, and its content is not given in the notice.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free